Momenta Pharmaceuticals, Inc. - News/Events - Press Releases

2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004

12/11/2018

Momenta Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriter’s Option to Purchase Additional Shares

12/06/2018

UPDATE: Momenta Pharmaceuticals Announces Pricing of Public Offering of Common Stock

12/05/2018

Momenta Pharmaceuticals Announces Proposed Public Offering of Common Stock

12/03/2018

Momenta Pharmaceuticals Provides Update on US Regulatory Strategy for M923, Proposed Biosimilar to HUMIRA®

11/07/2018

Momenta Pharmaceuticals Announces Publication of Phase 1 Study Data for Anti-FcRn Antibody, M281

11/07/2018

Momenta Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Corporate Update

11/06/2018

Momenta Pharmaceuticals Announces Global Settlement with AbbVie to Enable Commercialization of M923, a Proposed Biosimilar to HUMIRA® (adalimumab)

11/06/2018

Momenta Pharmaceuticals to Webcast Presentation at the Stifel 2018 Healthcare Conference

10/31/2018

Momenta Pharmaceuticals Announces Date of Third Quarter 2018 Financial Results Conference Call and Webcast

10/04/2018

Momenta Pharmaceuticals to Host R&D Day on October 11, 2018

10/01/2018

Momenta Pharmaceuticals Completes Strategic Review to Refocus its Operations and Drive Shareholder Value

08/09/2018

Momenta Pharmaceuticals Reports Second Quarter 2018 Financial Results and Provides Corporate Update

08/02/2018

Momenta Pharmaceuticals Announces Date of Second Quarter 2018 Financial Results Conference Call and Webcast

06/06/2018

Momenta Pharmaceuticals to Webcast Presentation at the Goldman Sachs 39th Annual Global Healthcare Conference

05/17/2018

Momenta Pharmaceuticals Announces Presentation on M281, an Anti-FcRn Monoclonal Antibody, at 11th International Congress on Autoimmunity

05/10/2018

Momenta Pharmaceuticals to Webcast Presentation at the Bank of America Merrill Lynch Health Care Conference 2018

05/08/2018

Momenta Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Corporate Update

05/01/2018

Momenta Pharmaceuticals Announces Date of First Quarter 2018 Financial Results Conference Call and Webcast

03/05/2018

Momenta Pharmaceuticals to Webcast Presentation at Two Upcoming Investor Conferences

02/21/2018

Momenta Pharmaceuticals Reports Fourth Quarter and Year End 2017 Financial Results and Provides Corporate Update

02/13/2018

Momenta Pharmaceuticals Announces FDA Approval and Launch of Glatopa® (glatiramer acetate injection) 40 mg/mL

02/08/2018

Momenta Pharmaceuticals to Webcast Presentation at the LEERINK Partners 7th Annual Global Healthcare Conference

02/07/2018

Momenta Pharmaceuticals Announces Date of Fourth Quarter and Year End 2017 Financial Results Conference Call and Webcast

01/30/2018

Momenta Pharmaceuticals Announces Positive Outcome for Contracted Glatopa® (glatiramer acetate injection) Fill/Finish Manufacturer

01/05/2018

Momenta Pharmaceuticals Reports Positive Top-Line Phase 1 Data Showing Proof of Mechanism for M281, an Anti-FcRn Monoclonal Antibody, in Healthy Volunteers

01/03/2018

Momenta and Mylan Announce Development Strategy for M710, a Proposed Biosimilar to EYLEA® (aflibercept)